Cargando…
Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia
Carbon monoxide (CO) at low, non-toxic concentrations has been previously demonstrated to exert anti-inflammatory protection in murine models of sickle cell disease (SCD). However CO delivery by inhalation, CO-hemoglobin infusion or CO-releasing molecules presents problems for daily CO administratio...
Autores principales: | Belcher, John D., Gomperts, Edward, Nguyen, Julia, Chen, Chunsheng, Abdulla, Fuad, Kiser, Zachary M., Gallo, David, Levy, Howard, Otterbein, Leo E., Vercellotti, Gregory M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181332/ https://www.ncbi.nlm.nih.gov/pubmed/30308028 http://dx.doi.org/10.1371/journal.pone.0205194 |
Ejemplares similares
-
Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease
por: Beckman, Joan D., et al.
Publicado: (2021) -
Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction
por: Belcher, John D., et al.
Publicado: (2018) -
The Fucosylation Inhibitor, 2-Fluorofucose, Inhibits Vaso-Occlusion, Leukocyte-Endothelium Interactions and NF-ĸB Activation in Transgenic Sickle Mice
por: Belcher, John D., et al.
Publicado: (2015) -
The BACH1 inhibitor ASP8731 inhibits inflammation and vaso-occlusion and induces fetal hemoglobin in sickle cell disease
por: Belcher, John D., et al.
Publicado: (2023) -
Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence
por: Gentinetta, Thomas, et al.
Publicado: (2022)